BGT226 may therefore represent a potential anticancer agent in HCC for its capability to target the hyperactivated PI3K/Akt/mTOR signaling pathway and to inhibit, in hypoxia microenvironment, increased translation and synthesis of proteins such as HIF-1α and VEGF, from which may depend tumor progression. Here, VEGFA is linked to neoplasm.